Daxor Corporation announces two significant new customer transactions with Daxor’s BVA-100 in January, marking a strong start to 2024. New wins include: Four-year lease agreement for the BVA analyzer at an award-winning network of 24 affiliated hospitals in Mississippi, West Tennessee, and East Arkansas with a reach into Kentucky, Missouri, and central Alabama; BVA analyzer purchase at a 200-bed independent hospital in Mississippi. “Our sales and marketing teams have kicked off the new calendar year with great momentum,” said Michael Feldschuh, Daxor’s CEO and President. “We remain focused on commercialization – broadening our reach with new analyzer purchases, and driving utilization within our current customer base, supported by our ezBVA Lab service.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DXR:
- Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions
- Daxor announces analyzer purchases in Q4
- Daxor awarded additional new patent for smart blood volume technology
- Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer
- Daxor submits dual 510k/CLIA-waiver application to FDA for Daxor BVA